Targeted, oral agent Enzastaurin shows favorable results

The data presented were gathered from a multicenter Phase II study of enzastaurin as a second- or third-line treatment of NSCLC (ASCO Abstract #7543 ). The rationale for the study was based on en-zastaurins unique mechanism of action as a serine/threonine kinase inhibitor, which is believed to suppress signaling through the PKC- and PI3K/AKT pathways. Historically, over-expression and ac-tivity of PKC- and PI3K/AKT have been associated with poor prognosis and treatment resistance in NSCLC. The primary objective of the study was progression-free survival at six months. Secondary endpoints were safety and overall survival at 12 months.

These data in NSCLC shed new light on the potential versatility of this agent, said Richard Gaynor, M.D., vice president, cancer research and global oncology platform leader for Lilly. Our objective with enzastaurin is to continue investigating the efficacy and safety of this unique molecule in order to determine the diseases where enzastaurin could have the most positive impact on patients.

In the study, patients received 500 mg of oral enzastaurin, once daily, until disease progression or un-acceptable toxicity occurred. In the 54 patients enrolled, the median progression-free survival was 1.9 months (95% Confidence Interval: 1.7-1.9) and the progression-free survival rate at six months was 14% (95% CI: 4.4%-23.6%). The median overall survival was 9.9 months (95% CI: 6.5-14.6). The overall survival rate at 12 months was 46.3% (95% CI: 32.1%-60.5%). The most common toxicity was fatigue. Additional toxicities observed included ataxia (n=1), thromboembolism (n=1), anemia (n=1) and dizziness.

Based on the encouraging survival and tolerability data gathered thus far, further evaluation of en-zastaurin in NSCLC, as a single agent or in combination, is warranted, said chief investigator for the study, Gerold Bepler, M.D., Ph.D., chief of thoracic oncology at the H. Lee Moffitt Cancer Center and Research In

Contact: Neil Hochman
CPR Worldwide

Page: 1 2

Related medicine news :

1. Shark cartilage shows no benefit as a therapeutic agent for lung cancer
2. Studies suggest investigational agent reduces disease activity in MS
3. Novel anti-oxidant and anti-inflammatory agent shows effectiveness on key endpoints in trial
4. MRI contrast agent can detect heart attack in the making
5. Contrast agent puts new light on diagnosing breast cancer
6. New reagent delivers a chemical breakthrough at FSU
7. High-resolution imaging with contrast agent shows promise in osteoarthritis research
8. Study suggests anesthetic agent may have rapid antidepressant effects
9. Alzheimers medication shows promise in treating nerve agent and pesticide poisoning
10. Cranberries contain possible anti-caries/anti-plaque agents
11. New contrast agents may be on horizon for better medical imaging

Post Your Comments:

(Date:10/18/2018)... ... October 18, 2018 , ... ... demonstrating the company’s automated preclinical image data analysis tool, InVivoAX™, for quantitative ... finds applications in preclinical imaging of small animal models of human disease. ...
(Date:10/17/2018)... ... , ... The Myers’ have been doing this for five years. This year’s event ... CA 91326. , “The Harvest Festival is another way we like to give back ... Children’s Hospital LA,” said Kris and Keith. , The event includes a 50/50 raffle, ...
(Date:10/16/2018)... ... October 16, 2018 , ... Bastyr University is pleased announce ... Health and Medicine’s (AIHM) Visionary Award for his passionate efforts in forging a ... selected as AIHM’s recipient of the Visionary Award due to his tireless effort ...
(Date:10/16/2018)... (PRWEB) , ... October 16, 2018 , ... ... First Healthcare Compliance, an attorney experienced in employment law, writes frequently on employment ... publications. Recently, she authored a chapter in the Health Care Compliance Professional's Manual ...
(Date:10/16/2018)... ... October 16, 2018 , ... ... and clinical research networking-technology company founded by patient-survivors, and The Avoca Group, ... in the clinical trial execution process, today announced its mutual collaboration that ...
Breaking Medicine News(10 mins):
(Date:10/16/2018)... ... October 16, 2018 , ... Founders of two of ... of algae-based omega-3 products, Ben Kelly of Algarithm Ingredients and Philip Bromley of ... on October 15. The title of their presentation was “Making Algal Omega-3’s Great ...
(Date:10/16/2018)... (PRWEB) , ... October 16, 2018 , ... ... training standards to an international multidisciplinary group of healthcare treatment providers who treat ... courses needed for certification in a live, two-day, 12-hour track at Symposium 2019. ...
(Date:10/13/2018)... ... October 13, 2018 , ... As news hits that the ... over the next five years, from $3200 million in 2017 to $7170 million in ... even help drive this growth further. This news comes hot on the heels of ...
Breaking Medicine Technology:
Cached News: